Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended June 30, 2025.

Original from: PR Newswire Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at ma..

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2025.

To support countries in their efforts to strengthen detection of TB disease and infection, the World Health Organization (WHO) has published an updated version of the WHO operational handbook on tuberculosis: module 3:diagnosis,to accompany the WHO consolidated guidelines on tuberculosis published earlier this year. The document provides laboratory personnel, clinicians and other clinical staff, as well as ministries of health and technical partners, with detailed guidance on implementing WHO evidence-based recommendations. Furthermore, it describes operational considerations for the use of WHO-recommended tests, providing an overview of all testing classes, presenting revised model algorithms, and outlining the steps and processes required to implement and scale up new tests and testing strategies.

1.6 Substance Abuse Categories Point-of-Care drugs of abuse testing is estimated at $576 million and is anticipated to grow at 2.4% over the next five years. It is anticipated that drug testing technology will b..

Tellgen Acquires Wuhan HealthCare Biotechnology for CNY 328 Million Tellgen Life (300642.SZ) announced plans to acquire a total of 82% equity in Wuhan HealthCare Biotechnology Co., Ltd., further expanding..

The World Health Organization this week issued a target product profile report for in vitro diagnostic tests to detect serious bacterial infections in newborns and babies aged 2 months and younger.

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 third quarter, which ended June 30, 2025.

Original from: QIAGEN · Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 - Net sales +6% CER (constant exchange rates) above outlook for at least +5% C..

Personalis reported after the close of the market on Tuesday a 24 percent year-over-year drop in second quarter revenues, missing analyst expectations and prompting the company to slash its full-year sales guidance.

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025.

Original from: QuidelOrtho Second Quarter 2025 Results (all comparisons are to the prior year period) · Total revenue was $614 million, as reported - Non-respiratory revenue was $567 ..

1.5 Gestation Category The most widely used professional and over the counter (OTC) patient self-tests for women’s health are pregnancy and ovulation tests. OTC includes tests offered by pharmacies and other re..

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025.

Roche on Monday announced that its Cobas Respiratory 4-flex test for SARS-CoV-2, influenza A/B, and respiratory syncytial virus has received clearance from the US Food and Drug Administration.

Wantai Bio’s Wind ESG Rating Soars to AA, Ranking in the Top 7% of Listed Companies in A-Share and Hong Kong Markets Recently, Wantai Bio achieved an upgrade to an AA rating in the presti..